Cargando…
Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials
SIMPLE SUMMARY: Mesenchymal chondrosarcoma (MCS) is a subtype of chondrosarcoma with rare occurrence and poor survival rates. MCS stains positive for S-100 and SOX9 as well as CD99, ezrin, and NKX2.2. Recurring fusion of the HEY1 and NCOA2 genes—involved in epigenetic modifications—was reported in M...
Autores principales: | Dudzisz-Śledź, Monika, Kondracka, Monika, Rudzińska, Monika, Zając, Agnieszka E., Firlej, Wiktoria, Sulejczak, Dorota, Borkowska, Aneta, Szostakowski, Bartłomiej, Szumera-Ciećkiewicz, Anna, Piątkowski, Jakub, Rutkowski, Piotr, Czarnecka, Anna M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527018/ https://www.ncbi.nlm.nih.gov/pubmed/37760551 http://dx.doi.org/10.3390/cancers15184581 |
Ejemplares similares
-
Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials
por: Zając, Weronika, et al.
Publicado: (2023) -
Epigenetic Abnormalities in Chondrosarcoma
por: Bereza, Michał, et al.
Publicado: (2023) -
Chondrosarcoma-from Molecular Pathology to Novel Therapies
por: Zając, Agnieszka E., et al.
Publicado: (2021) -
Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence
por: Borkowska, Aneta Maria, et al.
Publicado: (2022) -
Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies
por: Stachyra, Karolina, et al.
Publicado: (2021)